

---

## THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

---

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold or transferred** all your shares in Shanghai Junshi Biosciences Co., Ltd.\*, you should at once hand this circular, the accompanying form of proxy to the purchaser or transferee or to the bank, a licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

This circular appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

---



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

### **GENERAL MANDATE TO REPURCHASE H SHARES**

---

A letter from the Board is set out on pages 3 to 7 of this circular. The notices convening the EGM to be held at 15th Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai, the PRC on Monday, 27 July 2026 at 2:50 p.m. are set out on pages 11 to 12 of this circular.

The form of proxy for the EGM have been published on the websites of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and of the Company ([www.junshipharma.com](http://www.junshipharma.com)). Whether or not you are able to attend the EGM, you are reminded to complete, sign and return the form of proxy in accordance with the instructions printed thereon. For holders of H Shares, the form(s) of proxy for the EGM shall be lodged at the Company's H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 24 hours before the time fixed for holding the EGM or any adjournment thereof. Completion and return of the form(s) of proxy will not preclude you from attending the EGM and any adjournment thereof and voting in person.

Reference to times and dates in this circular are to Hong Kong local times and dates.

\* *For identification purposes only*

8 July 2026

---

## CONTENTS

---

|                                                                                                  | <i>Page</i> |
|--------------------------------------------------------------------------------------------------|-------------|
| <b>DEFINITIONS.....</b>                                                                          | <b>1</b>    |
| <b>LETTER FROM THE BOARD.....</b>                                                                | <b>3</b>    |
| <b>APPENDIX I – EXPLANATORY STATEMENT ON THE<br/>                    REPURCHASE MANDATE.....</b> | <b>8</b>    |
| <b>NOTICE OF 2026 FIRST EGM .....</b>                                                            | <b>11</b>   |

---

## DEFINITIONS

---

*Unless the context otherwise requires, the following expressions in this circular have the following meanings:*

|                                              |                                                                                                                                                                                                                                                                                                |
|----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “A Share(s)”                                 | ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are traded in RMB and are listed on the Shanghai Stock Exchange                                                                                                                             |
| “Articles of Association” or “Articles”      | the articles of association of the Company                                                                                                                                                                                                                                                     |
| “Board of Directors” or “Board”              | the Board of Directors of the Company                                                                                                                                                                                                                                                          |
| “Chairman”                                   | chairman of the Board of Directors                                                                                                                                                                                                                                                             |
| “Company”                                    | Shanghai Junshi Biosciences Co., Ltd.* 上海君實生物醫藥科技股份有限公司, a joint stock limited company established in the PRC with limited liability, the H Shares and A Shares of which are listed and traded on the main board of the Hong Kong Stock Exchange and the Shanghai Stock Exchange, respectively |
| “Director(s)”                                | the director(s) of the Company                                                                                                                                                                                                                                                                 |
| “EGM” or “2026 First EGM”                    | the extraordinary general meeting of the Company to be held on Monday, 27 July 2026 (and any adjournment thereof)                                                                                                                                                                              |
| “H Share(s)”                                 | overseas-listed share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are traded in Hong Kong dollars and are listed on the main board of the Hong Kong Stock Exchange                                                                                     |
| “H Shareholder(s)”                           | holder(s) of H Shares                                                                                                                                                                                                                                                                          |
| “Hong Kong”                                  | the Hong Kong Special Administrative Region of the PRC                                                                                                                                                                                                                                         |
| “Hong Kong Listing Rules” or “Listing Rules” | the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, as amended, supplemented or otherwise modified from time to time                                                                                                                                                |
| “Hong Kong Stock Exchange”                   | The Stock Exchange of Hong Kong Limited                                                                                                                                                                                                                                                        |
| “Notice of EGM”                              | the notice of the EGM dated 8 July 2026, a copy of which is set out on pages 11 to 12 of this circular                                                                                                                                                                                         |

---

## DEFINITIONS

---

|                           |                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “PRC” or “China”          | the People’s Republic of China which, for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region and Taiwan                                                                                                                                                                                                                     |
| “PRC Company Law”         | the Company Law of the PRC (《中華人民共和國公司法》), as amended, supplemented or otherwise modified from time to time                                                                                                                                                                                                                                                        |
| “Repurchase Mandate”      | the general mandate to exercise the power of the Company to repurchase, according to the repurchase plan to be determined by the Board of Directors, not exceeding 10% of the number of H Shares in issue (excluding treasury shares) as at the date of passing the proposed relevant resolution at the EGM, details of which are set out in the notice of the EGM |
| “RMB”                     | Renminbi, the lawful currency of the PRC                                                                                                                                                                                                                                                                                                                           |
| “Shanghai Stock Exchange” | the Shanghai Stock Exchange (上海證券交易所)                                                                                                                                                                                                                                                                                                                              |
| “Share(s)”                | ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising H Shares and A Shares                                                                                                                                                                                                                                       |
| “Shareholder(s)”          | holder(s) of Share(s)                                                                                                                                                                                                                                                                                                                                              |
| “treasury share(s)”       | has the meaning ascribed to it under the Listing Rules, as amended, supplemented or otherwise modified from time to time                                                                                                                                                                                                                                           |
| “%”                       | per cent                                                                                                                                                                                                                                                                                                                                                           |

---

## LETTER FROM THE BOARD

---



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

*Executive Directors:*

Mr. Xiong Jun (*Chairman and Legal Representative*)

Dr. Li Ning (*Vice Chairman*)

Dr. Zou Jianjun (*Chief Executive Officer and  
General Manager*)

Mr. Li Cong (*Co-Chief Executive Officer*)

Mr. Zhang Zhuobing

Dr. Wang Gang

Dr. Li Xin

*Registered address, headquarters and*

*principal place of business in the PRC:*

Level 4, No. 987, Cai Lun Road

China (Shanghai) Pilot Free Trade Zone

The PRC

*Principal place of business in Hong Kong:*

Room 1918, 19/F, Lee Garden One

33 Hysan Avenue

Causeway Bay

Hong Kong

*Non-executive Directors:*

Dr. Yao Sheng

Mr. Tang Yi

*Independent Non-executive Directors:*

Dr. Feng Xiaoyuan

Mr. Li Zhongxian

Dr. Yang Jin

Ms. Lu Kun

Mr. Chen Liang

*To the Shareholders*

Dear Sir or Madam,

### **I. INTRODUCTION**

The purpose of this circular is to provide you with information regarding the resolution to be proposed at the EGM to enable you to make informed decisions on whether to vote for or against the proposed resolution at the EGM.

---

## LETTER FROM THE BOARD

---

At the EGM, the following resolution will be proposed to consider and, if thought fit, approve:

### **Special Resolution**

- (1) the general mandate to repurchase H Shares.

## **II. DETAILS OF THE RESOLUTION**

### **(1) General mandate to repurchase H Shares**

In order to safeguard the interests of its Shareholders, taking into account market changes and the actual circumstances of the Company, and to facilitate the timely and flexible implementation of share repurchases by the Company, the Company plans to repurchase a portion of its H Shares in accordance with the laws and regulations, including the PRC Company Law and the Hong Kong Listing Rules, and its Articles of Association. It is proposed at the EGM to approve the grant to the Board of Directors of a general mandate to authorize the Board of Directors and any of its authorized persons to deal with all matters in connection with the repurchase of H Shares. Particulars of the Repurchase Mandate are as follows:

1. Subject to the restrictions under paragraphs 2 and 3 below, the Board shall be approved to exercise all rights of repurchasing the H Shares in issue and listed on the Hong Kong Stock Exchange of nominal value of RMB1.00 each within the Relevant Period in accordance with all applicable laws, regulations, rules and/or requirements (as amended from time to time) of relevant governmental or regulatory authorities of the PRC, the Hong Kong Stock Exchange or any other governmental or regulatory authorities.
2. The Board shall be authorized to repurchase H Shares in an amount not exceeding 10% of the total number of H Shares in issue (excluding any treasury shares) at the date of passing of such resolution at the EGM within the Relevant Period, and the repurchase price on any date of repurchase shall not be equal to or higher than 105% of the average closing price of H Shares traded on the Hong Kong Stock Exchange for the five preceding trading days.
3. The General Mandate shall include, without limitation, authority to:
  - (i) formulate and implement the specific repurchase plan, including but not limited to determining the timing of the repurchase, the duration of the repurchase, the number of H Shares to be repurchased, the price of the repurchase and the specific use of the repurchased H shares;
  - (ii) open an offshore stock account and deal with the relevant registration of changes in foreign exchange;
  - (iii) deal with such relevant approval and reporting formalities as may be required by the relevant regulatory authorities and the Hong Kong Stock Exchange (if necessary);

---

## LETTER FROM THE BOARD

---

- (iv) handle matters related to the cancellation of the repurchased H Shares, reduction of the registered share capital, amendment of the Articles of Association and relevant statutory registration and filing formalities both within and outside the PRC, and/or the holding of such shares as treasury shares based on market conditions and the Company's capital management needs at the relevant time of such share repurchase; and
- (v) execute and sign all such documents, do all such acts and matters and take all such steps relevant to the proposed repurchase of H Shares, as the Board of Directors considers expedient, necessary or desirable to give effect to such repurchase, in accordance with the relevant laws, regulations and rules;

For the purpose of this special resolution, "Relevant Period" means the period from the passing of the special resolution at the EGM until the earliest of:

- (i) the conclusion of the first annual general meeting of the Company following the approval of this special resolution; or
- (ii) the date on which the Repurchase Mandate given under the special resolution is revoked or varied by a special resolution of the Shareholders in general meeting.

Subject to the approval and authorization of the Repurchase Mandate being granted to the Board of Directors at the EGM, the Board of Directors proposes to authorize the Chairman and any of his authorized persons to exercise the authority granted to it at the EGM to deal with the Repurchase Mandate and all other matters which may be authorized by the Board in connection with the repurchase of H Shares.

An explanatory statement required under the Listing Rules to be issued to the Shareholders is set out in Appendix I to this circular. The explanatory statement contains information reasonably necessary to enable the Shareholders to make an informed decision on whether to vote in favor of or against the resolution.

### III. EGM

The EGM will be held at 15th Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai, the PRC at 2:50 p.m. on Monday, 27 July 2026. The Notice of EGM is set out on pages 11 to 12 of this circular and published on the websites of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and of the Company ([www.junshipharma.com](http://www.junshipharma.com)).

The form of proxy for use at the EGM are published on the websites of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and of the Company ([www.junshipharma.com](http://www.junshipharma.com)).

The Notice of the EGM has also been separately published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn/>).

---

## LETTER FROM THE BOARD

---

### IV. CLOSURE OF REGISTER OF MEMBERS OF H SHARES

The register of members of H Shares will be closed from Wednesday, 22 July 2026 to Monday, 27 July 2026, both days inclusive, during which period no transfer of H Shares will be registered, in order to determine the entitlements of the Shareholders to attend and vote at the EGM. The record date for determining the entitlement to attend and vote at the EGM will be Monday, 27 July 2026. In order to be eligible to attend and vote at the EGM, holders of H Shares whose transfer documents have not been registered are required to deposit all properly completed share transfer forms together with the relevant share certificates to the Company's H share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H shares) for registration before 4:30 p.m. on Tuesday, 21 July 2026.

### V. PROXY FORMS

A Shareholder entitled to attend and vote at the meeting may appoint one or more persons as his/her/its proxy(ies) to attend and vote on his/her/its behalf. A proxy need not be a shareholder of the Company but must attend the meeting in person to represent the member. Shareholders who intend to attend the meeting by proxy should complete the proxy form.

For holders of H Shares, the proxy form for the EGM should be returned to the Company's H Share registrar, Tricor Investor Services Limited at 17/F, Far East Centre, 16 Harcourt Road, Hong Kong, in person or by post as soon as possible and no later than 24 hours before the time fixed for holding the meeting (i.e. not later than Sunday, 26 July 2026 at 2:50 p.m. (Hong Kong time)) or any adjournment thereof. Completion and return of the proxy form(s) will not preclude you from attending the meeting and any adjournment thereof and voting in person. In such event, the form of proxy shall be deemed to be revoked.

### VI. VOTING BY POLL

According to Rule 13.39(4) of the Hong Kong Listing Rules, any vote of shareholders at a general meeting must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Accordingly, the chairman of the EGM will demand a poll for resolution to be proposed at the EGM in accordance with Article 74 of the Articles of Association. Poll results will be announced by the Company in the manner prescribed under Rule 13.39(5) of the Hong Kong Listing Rules after the EGM.

To the best of the Directors' knowledge, information and belief, none of the Shareholders are required to abstain from voting at the EGM.

---

## LETTER FROM THE BOARD

---

### VII. RECOMMENDATIONS

The Board also considers that the resolution set out in the Notice of EGM is fair and reasonable and in the best interests of the Company and its Shareholders as a whole. Accordingly, the Board recommends that the Shareholders to vote in favor of the resolution set out in the Notice of EGM.

### VIII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Hong Kong Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

### IX. FURTHER INFORMATION

Your attention is drawn to the appendix to this circular.

By Order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

8 July 2026

\* *For identification purposes only*

*This appendix serves as an explanatory statement, as required by the Hong Kong Listing Rules, to enable the Shareholders to make an informed decision on whether to vote for or against the grant of the Repurchase Mandate.*

## **I.     SHARE CAPITAL**

As at the Latest Practicable Date, the share capital of the Company was 1,026,689,871 comprising 766,394,171 A Shares and 260,295,700 H Shares. Subject to the passing of the proposed resolution for the Repurchase Mandate, on the basis that no further H Shares are issued on or prior to the EGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 26,029,570 H Shares, representing 10% of the number of H Shares in issue (excluding any treasury Shares) as at the date of passing of the resolution in relation to the Repurchase Mandate.

## **II.   REASON FOR THE REPURCHASE**

The Board believes that the Repurchase Mandate provides the Company with the flexibility to repurchase H Shares, which is in the interests of the Company and its Shareholders. Such repurchases may, depending on market conditions and funding arrangements at such time, lead to an enhancement of the net asset value per Share and/or earnings per Share. The repurchase of H Shares will only be made when the Directors believe such repurchase will benefit the Company and the Shareholders.

## **III. EXERCISE OF THE REPURCHASE MANDATE**

Subject to the passing of the special resolution in relation to the grant of the Repurchase Mandate to the Board at the EGM, the Board will be granted the Repurchase Mandate to be effective until the earlier of (1) the conclusion of the first annual general meeting of the Company following the approval of this special resolution; or (2) the date on which the Repurchase Mandate given under the special resolution is revoked or varied by a special resolution of the Shareholders in general meeting. The exercise of the Repurchase Mandate shall be subject to the approval of the relevant PRC regulatory authorities as required by the laws, rules and regulations of the PRC being obtained (if applicable).

## **IV.   FUNDING OF THE REPURCHASE**

In repurchasing its H Shares, the Company may only apply funds from the Company's internal resources legally available for such purpose in accordance with the Articles of Association, the Hong Kong Listing Rules and the applicable laws, rules and regulations of the PRC.

**V. IMPACT ON WORKING CAPITAL**

The Directors consider that there would not be a material adverse impact on the working capital or the gearing position of the Company in the event that the Repurchase Mandate is to be exercised in full at any time during the proposed repurchase period, as compared with the position disclosed in the latest published audited accounts contained in the annual report of the Company for the year ended 31 December 2025. However, the Directors do not propose to exercise the General Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital or the gearing position of the Company which in the opinion of the Directors are from time to time appropriate for the Company. The number of H Shares to be repurchased, the H Share price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regarded to the market circumstances then prevailing, in the best interests of the Company.

**VI. H SHARE PRICES**

The highest and lowest trading prices for the H Shares on the Hong Kong Stock Exchange during each of the previous 12 months preceding the Latest Practicable Date were as follows:

|                                          | <b>Highest Price</b><br><i>HK\$ per share</i> | <b>Lowest Price</b><br><i>HK\$ per share</i> |
|------------------------------------------|-----------------------------------------------|----------------------------------------------|
| <b>2025</b>                              |                                               |                                              |
| July                                     | 29.00                                         | 21.10                                        |
| August                                   | 37.86                                         | 23.50                                        |
| September                                | 38.64                                         | 28.70                                        |
| October                                  | 32.62                                         | 23.90                                        |
| November                                 | 27.68                                         | 23.04                                        |
| December                                 | 25.36                                         | 21.08                                        |
| <b>2026</b>                              |                                               |                                              |
| January                                  | 26.20                                         | 21.30                                        |
| February                                 | 22.96                                         | 20.08                                        |
| March                                    | 23.90                                         | 17.58                                        |
| April                                    | 30.80                                         | 23.60                                        |
| May                                      | 26.78                                         | 19.70                                        |
| June                                     | 22.00                                         | 15.25                                        |
| July (up to the Latest Practicable Date) | 20.38                                         | 17.85                                        |

**VII. STATUS OF REPURCHASED H SHARES**

The Company may cancel the H Shares bought back under the Repurchase Mandate, and/or hold them as treasury shares subject to certain conditions, for example, market conditions, purposes of share repurchase and capital management needs of the Group, at the relevant time of the share repurchase.

**VIII. SHARE REPURCHASES MADE BY THE COMPANY**

The Company had not purchased any Shares on the Hong Kong Stock Exchange or the Shanghai Stock Exchange or otherwise during the six months immediately preceding the Latest Practicable Date.

**IX. DIRECTORS' UNDERTAKING**

The Directors, so far as the same may be applicable, will exercise the power of the Company to make repurchases pursuant to the Repurchase Mandate in accordance with the Hong Kong Listing Rules, the Articles of Association and the applicable laws, rules and regulations of the PRC.

**X. DISCLOSURE OF INTERESTS**

To the best of knowledge of the Directors having made all reasonable enquiries, none of the Directors or their respective close associates has any present intention to sell to the Company any of the H Shares in the Company if the Repurchase Mandate is approved at the EGM.

As at the Latest Practicable Date, no core connected person of the Company has notified the Company that he/she/it has a present intention to sell any H Shares nor has such core connected person undertaken not to sell any of the securities held by him/her/it to the Company in the event that the Repurchase Mandate is granted.

**XI. IMPLICATIONS UNDER THE TAKEOVERS CODE**

If a Shareholder's proportionate interest in the voting rights of the Company increases on the Company exercising its powers to repurchase securities pursuant to the Repurchase Mandate, such increase will be treated as an acquisition for the purposes of Rule 26 of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, the Directors are not aware of any consequence which may arise under the Takeovers Code and any similarly applicable laws as a consequence of any repurchase of Shares under the Repurchase Mandate.

The Company confirms that neither this Explanatory Statement nor the Repurchase Mandate has any unusual features.

---

## NOTICE OF 2026 FIRST EGM

---

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

### **NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that the 2026 first extraordinary general meeting (the “EGM”) of Shanghai Junshi Biosciences Co., Ltd.\* (the “**Company**”) will be held at 15th Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai, the People's Republic of China on Monday, 27 July 2026 at 2:50 p.m., for the following purposes:

#### **SPECIAL RESOLUTION<sup>(9)</sup>**

1. The proposal in relation to the general mandate to repurchase the Company's H Shares.

By Order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, PRC, 8 July 2026

---

## NOTICE OF 2026 FIRST EGM

---

*Notes:*

1. Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”), any vote of shareholders at a general meeting will be taken by poll. As such, the resolution set out in the notice of EGM will be voted by poll. Results of the poll will be published on the Company’s website at [www.junshipharma.com](http://www.junshipharma.com) and the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) after the EGM in accordance with the Listing Rules.
2. The register of members of H shares of the Company will be closed from Wednesday, 22 July 2026 to Monday, 27 July 2026, both days inclusive, during which period no transfer of H shares of the Company will be registered, in order to determine the entitlements of the shareholders of the Company to attend and vote at the EGM. The record date for determining the entitlement to attend and vote at the EGM will be Monday, 27 July 2026. In order to be eligible to attend and vote at the EGM, all transfers of H shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company’s H share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H shares) before 4:30 p.m. on Tuesday, 21 July 2026, being the last share registration date.
3. A shareholder entitled to attend and vote at the meeting may appoint one or more persons as his/her proxy(ies) to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company but must attend the meeting in person to represent the member.
4. The instrument appointing a proxy must be in writing and signed by the appointing shareholder or his duly authorized attorney in writing. Where the appointing shareholder is a legal entity, such instrument must be either under its common seal or duly signed by its legal representative, director(s) or duly authorized attorney(s).
5. Shareholders who intend to attend the meeting by proxy should complete the proxy form. For holders of H shares, the proxy form should be returned to the Company’s H Share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, in person or by post as soon as possible not less than 24 hours before the time fixed for holding the meeting or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending the meeting and any adjournment thereof and voting in person. In such event, the form of proxy shall be deemed to be revoked.
6. The EGM is expected to last for less than half a day. Shareholders (in person or by proxy) who attend the EGM should bear their own transportation and accommodation expenses. Shareholders or their proxies attending the EGM shall present their identification documents.
7. Where there are joint registered holders of any share, any one of such persons may vote at the meeting, either in person or by proxy, in respect of such share as if he/she were solely entitled thereto; but if more than one of such joint holders be present at the meeting, the vote of the senior holder who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.
8. Unless otherwise stated, capitalized terms used herein shall have the same meanings as that defined in the circular of the Company dated 8 July 2026 (“**Circular**”). References to times and dates in this notice are to Hong Kong local times and dates.
9. Further details of the resolution have been included in the Circular.
10. This notice of EGM is despatched to the holders of H shares only. The notice of EGM to the holders of A Shares is separately published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn/>).

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.*

\* For identification purpose only.